TrialESMO open2026

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

M Van Houdt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.